Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy (Q33883229)

29 July 2017

title

Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy (English)

1 reference

metastatic renal cell carcinoma

29 July 2017

1 reference

1 reference

S L Richey

1

1 reference

29 July 2017

S H Culp

2

1 reference

29 July 2017

E Jonasch

3

1 reference

29 July 2017

P G Corn

4

1 reference

29 July 2017

L C Pagliaro

5

1 reference

29 July 2017

P Tamboli

6

1 reference

29 July 2017

K K Patel

7

1 reference

29 July 2017

S F Matin

8

1 reference

29 July 2017

C G Wood

9

1 reference

29 July 2017

N M Tannir

10

1 reference

29 July 2017

publication date

29 November 2010

1 reference

29 July 2017

1 reference

29 July 2017

volume

22

1 reference

29 July 2017

issue

5

1 reference

29 July 2017

page(s)

1048-1053

1 reference

Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study

29 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Palliative percutaneous kidney embolization with enbucrilate in patients with renal cell carcinoma: safety and symptom control

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal artery embolisation in the palliative treatment of renal carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Sorafenib in advanced clear-cell renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

The role of transarterial embolization in the treatment of renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Renal cell carcinoma with retroperitoneal lymph nodes. Impact on survival and benefits of immunotherapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Prognostic evaluation of transcatheter arterial embolization for unresectable renal cell carcinoma with distant metastasis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Transcatheter arterial embolization of unresectable renal cell carcinoma with a mixture of ethanol and iodized oil.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

5 July 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ563

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ563

Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ563

A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/ANNONC/MDQ563

Prognostic factors for survival in patients with brain metastases from renal cell carcinoma

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4092250

29 October 2018

Identifiers

DOI

10.1093/ANNONC/MDQ563

1 reference

29 July 2017

1 reference

29 July 2017

1 reference